LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

7.62 -0.13

Buy Sell

Overview

Share price change

24h

Current

Min

7.55

Max

7.62

Key metrics
By Trading Economics
Income	5.1M 5.1M
Sales	18M 163M
Profit margin	3.113
Employees	580
EBITDA	7.2M 28M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+129.36% upside

Dividends
By Dow Jones
Next Earnings	3 lis 2025

Market Stats
By TradingEconomics
Market Cap	-172M 1.7B
Previous open	7.75
Previous close	7.62

News Sentiment

By Acuity

50%

132 / 371 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2025, 18:25 UTC

Major Market Movers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 wrz 2025, 07:00 UTC

Earnings

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 wrz 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 wrz 2025, 20:54 UTC

Earnings

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 wrz 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 wrz 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 wrz 2025, 19:53 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 19:40 UTC

Earnings

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 wrz 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 wrz 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 wrz 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 wrz 2025, 18:50 UTC

Market Talk

Earnings

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 wrz 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 wrz 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 wrz 2025, 16:56 UTC

Market Talk

Earnings

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 wrz 2025, 16:41 UTC

Market Talk

Earnings

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 wrz 2025, 16:26 UTC

Earnings

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 wrz 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 wrz 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26 wrz 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26 wrz 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

129.36% upside

12 Months Forecast

Average 17.5 USD 129.36%

High 30 USD

Low 12 USD

Based on 6 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

132 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.